Navigation Links
Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal(TM) for Fabry Disease at ACMG 2009 Annual Meeting
Date:3/28/2009

Data provide support for expected Phase 3 program

CRANBURY, N.J., March 28 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) announced today positive results from its ongoing Phase 2 extension study of its investigational drug, Amigal(TM) (migalastat HCL) for Fabry disease. The results will be presented at the American College of Medical Genetics (ACMG) 2009 Annual Meeting in Tampa, FL.

Phase 2 Extension Study Overview:

Twenty-six subjects completed either 12 or 24 weeks of treatment during Phase 2 studies. Twenty-three of the 26 subjects continue to receive treatment in an ongoing extension study designed to evaluate the long term safety and efficacy of Amigal. Ten of the 23 subjects have been on treatment for at least 2 years and 4 subjects have been on treatment for more than 3 years.

Preliminary Results:

Treatment with Amigal was generally well-tolerated, with no drug-related serious adverse events. The most common adverse events were headache, arthralgia and diarrhea.

Subjects identified as responders to Amigal at the completion of the Phase 2 studies continued to maintain elevated levels of the target enzyme (a-Gal A), as measured in white blood cells, and reduced levels of the target substrate (kidney GL-3), as measured in urine.

A reduction of GL-3 levels was also observed in interstitial capillary cells from kidney biopsies. Previously reported Phase 2 results indicated that little to no GL-3 was detected in these cells in most subjects prior to treatment with Amigal. The new data were obtained from the retesting of biopsies using an improved methodology.

Preliminary results from the evaluation of modified doses and a new dosing regimen were also presented.

Derralynn
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Amicus Therapeutics to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
2. Amicus Therapeutics Announces Change to Board of Directors
3. Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
4. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
5. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
6. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
7. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
8. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
9. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
10. Amicus Therapeutics Opens Research Facility in San Diego
11. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... September 01, 2015 , ... AxioMx Inc. , a ... Institutes of Health (NIH) has awarded the company a Phase I Small Business ... Institute of Diabetes and Digestive and Kidney Diseases. AxioMx will use this award ...
(Date:9/1/2015)... ... September 01, 2015 , ... Knowledgent , the data and analytics ... advanced analytics utilizing data lakes in the healthcare industry. , As the Internet of ... of data over the last few years as more entities become technology enabled through ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... from University of California Los Angeles, Boston University School of Medicine, Frederick National ... in PLOS One, the world’s first multidisciplinary Open Access journal. , Christopher ...
(Date:8/31/2015)... GUELPH, ON , Aug. 31, 2015 /PRNewswire/ - BIOREM ... new orders totalling $5.7 million. The orders are for air emission ... "Of particular note is a large order for a ... our equipment will be replacing a competitor,s system that failed ... see in our engineered solutions," said Derek S. Webb ...
Breaking Biology Technology:AxioMx Announces Receipt of SBIR Grant for DNA-Protein Complex Antigen Development 2AxioMx Announces Receipt of SBIR Grant for DNA-Protein Complex Antigen Development 3New White Paper Explores Data Lake Opportunities in the Healthcare Industry 2Synedgen’s Director for Pharmaceutical Manufacturing Publishes New Research 2Synedgen’s Director for Pharmaceutical Manufacturing Publishes New Research 3
... Tomorrow,s television and computer screens could be brighter, clearer ... developed by a team of researchers from Canada and ... The synthesis of a conjugated organic polymer--widely used as ... and solar cells--could mean more efficient, cheaper electronics. ...
... China , July 19 /PRNewswire/ - Aegera Therapeutics Inc. ... its Phase 1-2 Study of the novel targeted therapeutic, AEG35156, given ... liver cancer). , , ... This study, entitled "A Phase 1-2, Open-Label Study of The X-Linked ...
... SAN DIEGO , July 19 "Amira Pharmaceuticals, ... GlaxoSmithKline, has achieved two clinical development milestones." , ... These milestones are related to the successful progression of the program to ... in patients suffering from asthma.   , ...
Cached Biology Technology:Polymer synthesis could aid future electronics 2Aegera Therapeutics Reports Survival Data from the Phase 1 Portion of its Phase 1-2 Study of AEG35156 in Combination with Sorafenib in Patients with Advanced Hepatocellular Carcinoma 2Aegera Therapeutics Reports Survival Data from the Phase 1 Portion of its Phase 1-2 Study of AEG35156 in Combination with Sorafenib in Patients with Advanced Hepatocellular Carcinoma 3Amira Pharmaceuticals Hits Two Development Milestones Related to FLAP Inhibitor Program 2
(Date:8/12/2015)... 2015   MedNet Solutions , an innovative SaaS-based ... clinical research, is proud to announce that ... eClinical technology platform, has led the way to significant ... of 2015.   Q2 2015 and Q1 2015 were, ... contract value sold in the company,s 15 year history.  ...
(Date:8/12/2015)... 2015  New research unveiled at Black Hat ... to steal users, fingerprints. Information released today by ... scanners on mobile devices, making the security of ... on mobile devices, HYPR Corp. recently released a ... systems with strong cryptographic security. More information on ...
(Date:8/11/2015)... , August 11, 2015 Today, ZUK ... Already received as well as expected revenues in 2015 that relate ... FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a prominent smartphone manufacturer in ... ZUK selected FPC1 155 for ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2
... by the ancient Romans, researchers at the University ... ultra-sensitive tool for chemical, DNA, and protein analysis. ... for the first time, becomes colorimetric sensing, requiring ... explained Logan Liu, an assistant professor of electrical ...
... developed a new medical tool which could help surgeons ... have developed a dye which provides a quick and ... is an important anti-coagulant which has a significant role ... Chemistry at York have used inspiration from biological systems ...
... February 13, 2013, Cleveland: Cleveland Clinic researchers have found ... genetic screening for Lynch syndrome, the most common hereditary, ... online version of the Journal of Clinical Oncology ... cause of colon cancer in adults. The study found ...
Cached Biology News:The world's most sensitive plasmon resonance sensor inspired by ancient Roman cup 2The world's most sensitive plasmon resonance sensor inspired by ancient Roman cup 3Research shows how 'Mallard' dye fills need for speed 2Cleveland Clinic develops clinical screening program for no.1 genetic cause of colon cancer 2Cleveland Clinic develops clinical screening program for no.1 genetic cause of colon cancer 3
... label transfer is fast emerging as a ... and confirmation. Until now, only amino groups ... label transfer reagents such as our Sulfo-SBED. ... Mts-Atf-LC-Biotin, are exciting additions to the protein ...
...
... is a compact benchtop and stackable ... controller with a large display screen ... speed. Air circulation inside to evenly ... can be easily calibrated from the ...
...
Biology Products: